Bladder cancer (BC) is a commonly occurring malignant tumor affecting the urinary tract. Zinc finger proteins (ZNFs) constitute the largest transcription factor family in the human genome and are therefore attractive biomarker candidates for BC prognosis.
Bladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable biomarkers to better determine BCa extension. Prostate-specific membrane antigen (PSMA) appears to fulfill this requirement in prostate cancer but its role in BCa has not been established yet.
Phillip Koo: Welcome to UroToday. My name is Phillip Koo, and I have the pleasure of serving as a moderator for a special program titled, Detection and Localization of Prostate Cancer: Case Review Scans, Pearls and Pitfalls. So, as we’re all aware, the imaging landscape in prostate cancer has rapidly changed. Axumin fluciclovine was approved […]
Phillip Koo: Welcome to UroToday. My name is Phillip Koo and I have the pleasure of serving as a moderator for a special program, titled Detection and Localization of Prostate Cancer: Case Review of Scans, Pearls, and Pitfalls. So as we’re all aware, the imaging landscape in prostate cancer has rapidly changed. Axumin fluciclovine was […]
Phillip Koo: Welcome to UroToday. My name is Phillip Koo and I have the pleasure of serving as the moderator for a special program, entitled, Detection and Localization of Prostate Cancer, Case Review of Scans, Pearls, and Pitfalls. So as we’re all aware, the imaging landscape in prostate cancer has rapidly changed. Axumin and fluciclovine was […]
Ashish Kamat: Hello, and welcome to Uro Today’s is Bladder Cancer Center of Excellence. I’m Ashish Kamat, Professor of Urologic Oncology and Cancer Research at MD Anderson Cancer Center in Houston, Texas, and it’s my pleasure today to invite Dr. Amir Horowitz, who is a part of the Department of Oncological Sciences, and Dr. John Sfakianos, […]
Kidney stone disease comprising nephrolithiasis and nephrocalcinosis is a clinical syndrome of increasing prevalence with remarkable heterogeneity. Stone composition, age of manifestation, rate of recurrence, and impairment of kidney function varies with underlying etiologies.
Urinary tract stone disease (UTSD) is seen with increasing frequency in children, and genetic, metabolic and environmental factors are known to play a role in its etiology. Since it is a genetically heterogeneous disease, we investigated the multigene panel and metabolic evaluation together.
In short bowel syndrome (SBS) treated with parenteral nutrition (PN), multiple complications can occur. The etiology of kidney stones may be linked to the underlying disease (mesenteric thrombosis, surgical complications and injury, complications of therapy for cancer, Crohn’s disease), metabolic abnormalities resulting from morphological and functional changes in the gastrointestinal tract, and to treatment used.
Several studies have reported associations between vascular calcifications and urinary stone disease (USD). However, results have been inconsistent and the majority of studies did not report on race/ethnicity.
